Innovative Treatment Utilizing an Autologous Blood Clot for Diabetic Foot Ulcers

Abstract

Introduction. Diabetic foot ulcer is a complex wound that requires considerable effort to restart a stalled healing process. In this study, a TABCT product was used in a point-of-care setting to treat DFUs by reconstructing the ECM and adjusting intricate phenotypes and mechanisms of mediators to progress towards complete healing. The mechanism of action consists of reconstruction of the ECM, which protects the wound area from further destruction while it incorporates into the ulcer to promote granulation over exposed vital structures (ie, tendons, bone, and neurovascular structures). Objective. The authors evaluated the efficacy of the TABCT product in the management of DFUs. Materials and Methods. Study participants were wound care patients in hospitals and clinics across the United States and Israel as part of a registry study (ClinicalTrials.gov: NCT04699305). Twenty-nine patients age 18 years or older with chronic DFUs were included. A blood clot was created using the patient’s own peripheral blood in a point-of-care setting. An 18-mL blood sample was drawn from the patient and incorporated with calcium gluconate and kaolin to form a clot. Efficacy and superiority levels in PAR at week 4 and week 12 over the SOC treatment were established using the Agresti-Coull confidence interval. Results. Treatment of DFUs using the TABCT product resulted in 22 patients (75.86%) achieving 50% PAR at week 4 and showed superiority when compared with SOC data in previously published studies. Complete closure was achieved in 28 wounds (95%) at week 12. Conclusion. In the current study, TABCT exhibited superiority over SOC treatment and provided granulation over vital structures with a reduction in overall wound size in a timely manner via incorporation and stimulation of the body’s own healing capabilities.

A Prospective, Single-Arm Study to Evaluate the Safety and Efficacy of RD2-Ver.02, an Autologous Blood Clot, in the Treatment of Anal Fistula

“…Previous studies have demonstrated the safety and efficacy of this technology in treating challenging nonhealing cutaneous wounds [12][13][14][15][16][17] and complex surgical wounds. 33 Using autologous blood clots, which provide a transient scaffold and recruit surrounding cells to activate wound healing, 32 presents a promising strategy to treat open and chronic wounds.…”

“…12 The treatment was found to be safe and effective in acute and chronic soft tissue wounds. [13][14][15][16][17] The blood clot product is applied to the entire wound surface, thus creating a temporary scaffold and matrix to facilitate tissue healing. 18 In this study, we aimed to explore the safety and efficacy of RD2 ver.02 treatment for closure of simple and complex transsphincteric anal fistula.…”

Terapia Do Coágulo Sanguíneo Autólogo Na Cicatrização De Lesões: Revisão De Escopo

“…A terapia tópica do coágulo sanguíneo autólogo (TTCSA), comercializado com nome de Actigraft ® , consiste em um coágulo de sangue total criado a partir de sangue periférico do próprio paciente, que atua como ambiente protetor, imitando as propriedades da matriz extracelular, promovendo diminuição da intensidade da dor através da modulação da inflamação. Este coágulo autólogo é capaz de converter macrófagos M1 em M2 que secretam citocinas anti-inflamatórias, progredindo a ferida para fase proliferativa da cicatrização, proporcionando desta forma um fechamento rápido e mais eficiente que o tratamento convencional (7,8) .…”